REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
February 26, 2020 4:44 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.72), $0.28 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $11.77 million versus the consensus estimate of $39.67 million.
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery... More